Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open-Label Trial of Linezolid versus Ampicillin-Sulbactam/Amoxicillin- Clavulanate

Clinical Infectious Diseases

Volumn 38, Issue 1, 2004, Pages 17-24

  Lipsky, Benjamin A ^a   Itani, Kamal ^b   Norden, Carl ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; LINEZOLID; SULTAMICILLIN;

ADULT; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; GRAM POSITIVE COCCI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ACETAMIDES; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; AMPICILLIN; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; FOOT DISEASES; HUMANS; OXAZOLIDINONES; SULBACTAM; TREATMENT OUTCOME;

EID: 0346422351     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380449     Document Type: Article

References (30)

1. Lipsky BA. Infectious problems of the foot in diabetic patients. In: JH Bowker, MA Pfeifer, eds. The diabetic foot. 6th ed. St. Louis, MO: Mosby, 2001:467-30.
2. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997; 25:1318-26.
3. Smith DM, Weinberger M, Katz BP. Predicting nonelective hospitalization: a model based on risk factors associated with diabetes mellitus. J Gen Intern Med 1987; 2:168-73.
4. Reiber GE. Epidemiology of foot ulcers and amputations in the diabetic foot. In: JH Bowker, MA Pfeifer, eds. The diabetic foot. 6th ed. St. Louis, MO: Mosby, 2001:13-32.
5. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998; 21:42-8.
6. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150:790-7.
7. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990; 4:409-32.
8. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infec-tions. FEMS Immunol Med Microbiol 1999; 26:267-76.
9. Fluckiger U, Widmer AF. Epidemiology of methicillin-resistant Staphylococcus aureus. Chemotherapy 1999; 45:121-34.
10. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci: epidemiology, molecular mechanisms, and clinical relevance. Infect Dis Clin North Am 1997; 11:813-49.
11. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJM. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999; 16:767-71.
12. Mantey I, Hill RL, Foster AV, Wilson S, Wade JJ, Edmonds ME. Infection of foot ulcers with Staphylococcus aureus associated with increase mortality in diabetic patients. Commun Dis Public Health 2000; 3:288-90.
13. Wagner A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections [in German]. Dtsch Med Wochenschr 2001; 126:1353-6.
14. Fejfarová V, Jirkovská A, Skibová J, Petkov V. Pathogen resistance and other risk factors in the frequency of lower limb amputations in patients with the diabetic foot syndrome [in Czech]. Vnitr Lek 2002; 48:302-6.
15. Dang CN, Prasad YD, Boulton AW, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20:159-61.
16. Sesin GP, Paszko A, O'Keefe E. Oral clindamycin and ciprofloxacin therapy for diabetic foot infections. Pharmacotherapy 1990; 10:154-6.
17. Peterson LR, Lissack LM, Canter K, Fasching CE, Clabots C, Gerding DN. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am J Med 1989; 86:801-8.
18. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Linezolid Nosocomial Pneumonia Study Group. Clin Infect Dis 2001; 32:402-12.
19. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Linezolid Skin and Soft Tissue Infections Study Group. Antimicrob Agents Chemother 2000; 44:3408-13.
20. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Linezolid MRSA Study Group. Clin Infect Dis 2002; 34:1481-90.
21. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.
22. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73-7.
23. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50:747-50.
24. Arlington Medical Resources (AMR). The US hospital anti-infective market guide (USA and Europe editions). Malvern, PA: AMR, 2003. Available at: http://www.amr-data.com. Accessed March 2002.
25. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25(Suppl 1):S5-20.
26. West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm 1995; 52:1199-207.
27. Ramirez JA. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy. Pharmacotherapy 2001; 21:79S-82S.
28. Mason J, O'Keeffe C, Hutchinson A, McIntosh A, Young R, Booth A. A systemic review of foot ulcer in patients with type 2 diabetes mellitus. II. Treatment. Diabet Med 1999; 16:889-909.
29. Eneroth M, Apelqvist J, Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 1997; 18:716-21.
30. Eneroth M, Larsson J, Apelqvist J. Deep foot infections in patients with diabetes and foot ulcer: an entity with different characteristics, treatments, and prognosis. J Diabetes Complications 1999; 13:254-63.